THE EFFECT OF BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (bDMARDs) IN TARGETING DISEASE REMISSION IN AXIAL SPONDYLOARTHRITIS (axSpA): A SYSTEMATIC LITERATURE REVIEW (SLR)

被引：0
|
作者：
Cruz-Machado, A. R. [1 ,2 ]
Manica, S. R. [3 ]
Silva, J. L. [4 ]
Pimentel-Santos, F. M. [3 ]
Tavares-Costa, J. [4 ]
Vieira-Sousa, E. [1 ,2 ]
机构：
[1] Hosp Santa Maria, CHLN, Serv Reumatol & Doencas Osseas Metab, Lisbon, Portugal
[2] IMM, UIR, Lisbon, Portugal
[3] Ctr Hosp Lisboa Ocidental, Hosp Egas Moniz, Rheumatol Dept, Lisbon, Portugal
[4] Rheumatol Dept, Unidade Local Saude Alto Minho, Ponte do Lima, Portugal
来源：
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY | 2018年 / 36卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P88
引用
收藏
页码：731 / 731
页数：1
相关论文
共 50 条
  • [31] Effectiveness of conventional disease-modifying antirheumatic drugs in psoriatic arthritis: A systematic review
    Maese, Jesus
    Diaz del Campo, Petra
    Seoane-Mato, Daniel
    Guerra, Mercedes
    Canete, Juan D.
    REUMATOLOGIA CLINICA, 2018, 14 (02): : 81 - 89
  • [32] >Efficacy of disease-modifying antirheumatic drugs in the treatment of granulomatous mastitis: a systematic review
    Parperis, Konstantinos
    Costi, Egli
    Philippou, Sofia
    Hadi, Mohanad
    Derk, Chris T.
    RHEUMATOLOGY INTERNATIONAL, 2024, 44 (11) : 2371 - 2379
  • [33] Disease-Modifying Antirheumatic Drugs for the Management of Takayasu Arteritis - Protocol for a Systematic Review
    Rathore, Upendra
    Patro, Pallavi
    Agarwal, Vikas
    Sharma, Aman
    Misra, Durga Prasanna
    INDIAN JOURNAL OF RHEUMATOLOGY, 2021, 16 (01) : 79 - 82
  • [34] Cost Effectiveness Analysis of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis. A Systematic Review Literature
    Benucci, Maurizio
    Saviola, Gianantonio
    Manfredi, Mariangela
    Sarzi-Puttini, Piercarlo
    Atzeni, Fabiola
    INTERNATIONAL JOURNAL OF RHEUMATOLOGY, 2011, 2011
  • [35] Conventional and Biologic Disease-Modifying Antirheumatic Drugs Are Not Associated With Increase in or Progression of Cervical Neoplasia Among Patients With Spondyloarthritis
    Li, Philip Hei
    Chan, Shirley Chiu Wai
    Lau, Chak Sing
    Seto, Mimi Tin Yan
    Chung, Ho Yin
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2022, 28 (01) : E63 - E68
  • [36] Cost-Effectiveness of Biologic Response Modifiers Compared to Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis: A Systematic Review
    van der Velde, Gabrielle
    Pham, Ba'
    Machado, Marcio
    Ieraci, Luciano
    Witteman, William
    Bombardier, Claire
    Krahn, Murray
    ARTHRITIS CARE & RESEARCH, 2011, 63 (01) : 65 - 78
  • [37] Effects of Biologic Agents and Other Disease-Modifying Antirheumatic Drugs on Cardiovascular Outcomes in Psoriasis and Psoriatic Arthritis: A Systematic Review
    Armstrong, April W.
    Brezinski, Elizabeth A.
    Follansbee, Matthew R.
    Armstrong, Ehrin J.
    CURRENT PHARMACEUTICAL DESIGN, 2014, 20 (04) : 500 - 512
  • [38] TIME TO INITIATION OF BIOLOGIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN THE FRENCH COHORT ESPOIR
    Joanna, Kedra
    Granger, Benjamin
    Emilie, Stephanie
    Gaujoux-Viala, Cecile
    Rat, Anne-Christine
    Combe, Bernard
    Fautrel, Bruno
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1147 - 1148
  • [39] Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs)
    Adami, Giovanni
    Fassio, Angelo
    Rossini, Maurizio
    Bertelle, Davide
    Pistillo, Francesca
    Benini, Camilla
    Viapiana, Ombretta
    Gatti, Davide
    RMD OPEN, 2023, 9 (01):
  • [40] Development and Validation of Adherence Score for Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs
    Razak, Salmi Abdul
    Bakry, Mohd Makmor
    Said, Mohd Shahrir Mohamed
    Tan, Chai-Eng
    Redzuan, Adyani Md
    FRONTIERS IN PHARMACOLOGY, 2020, 11
12345